Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Jolles

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Molecular Medicine|June 23, 2007
Current strategies in TB immunotherapyEleanor Roy, Douglas B Lowrie, Stephen R Jolles
Immunobiology|August 2, 2011
Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patientsMichael L Beeton, Mohamed R Daha, Tariq El-Shanawany, et al.
Transplantation|March 14, 2022
An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas TransplantsArgiris Asderakis, Usman Khalid, Georgios Koimtzis, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Molecular Medicine|June 23, 2007
Current strategies in TB immunotherapyEleanor Roy, Douglas B Lowrie, Stephen R Jolles
Immunobiology|August 2, 2011
Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patientsMichael L Beeton, Mohamed R Daha, Tariq El-Shanawany, et al.
Transplantation|March 14, 2022
An Analysis of Serological Response and Infection Outcomes Following Oxford-AstraZeneca (AZD1222) and Pfizer-BioNTech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Kidney-pancreas TransplantsArgiris Asderakis, Usman Khalid, Georgios Koimtzis, et al.
Pageof 1